美媒:55岁糖尿病患者通过古饮食顺利摆脱糖尿病药物,血糖变正常

2018-02-01 Lily 来宝网

流行的古食谱可以帮助糖尿病患者更好地控制血糖。2009年,55岁的史蒂夫被诊断出患有2型糖尿病。

古食谱能帮助糖尿病吗?】流行的古食谱可以帮助糖尿病患者更好地控制血糖。2009年,55岁的史蒂夫被诊断出患有2型糖尿病

诊断出2型糖尿病的几个月后,史蒂夫放弃了传统的糖尿病饮食,也就是青睐高蛋白、低碳水化合物的饮食计划,开始遵循一种成为“穴居人饮食”的计划,也就是减少加工食品,强调肉类和蔬菜的饮食。一个月之内,库克能够停止服用所有药物,包括糖尿病、高血压、高胆固醇。他仍然定期检查血糖,而且总是在正常范围内。

古食谱对糖尿病的潜在益处

史蒂夫并不是一个个例。近年来,古食谱的流行迅速上升,许多支持者鼓吹这种方法是改善健康和减肥的有效途径。研究表明,2型糖尿病患者遵循“穴居人饮食”能够改善他们的血压、血糖水平。

研究人员无法清晰的解释为什么古饮食者有更好的健康结果,为什么古饮食比别的食谱更适合2型糖尿病患者。

研究人员表示:“我们相信,有多种因素参与,包括更多的纤维,从肠道降低了更多的糖吸收,更多的营养素和抗氧化剂记忆肠道微生态都有健康的影响。”这些研究结果表明,并不是所有的碳水化合物都是平等的。水果和蔬菜中的碳水化合物含有抗氧化剂和微量营养素,它们比小麦面包或谷类中的碳水化合物更好。

同样的研究还发现古饮食中的瘦肉等食物可以短期内提高胰岛素敏感性以及2型糖尿病患者的血脂水平。

2型糖尿病患者遵循古饮食可能会发现有助于他们更好地控制血糖,这种饮食基本上属于整种未经加工,这是一种健康的方法。另外,“笨重”的食品可能意味着你会充分感受到热量,有助于减肥,这也有利于2型糖尿病。

为什么有些专家对古希腊持怀疑态度?

然而,由于这种饮食计划几乎完全消除了某些食物组,如谷物,传统的智慧会争辩说,它没有健康饮食好。很多营养专家会说古饮食不均衡。许多版本的古食谱也鼓励食用红肉、全脂奶制品和饱和脂肪,如黄油,这可能会导致胆固醇水平升高。

对于糖尿病患者来说,这可能是一个特别危险的问题,因为他们比没有糖尿病的人更容易患心脏病。“对于糖尿病患者来说,主要的目标是控制血糖,但第二个目标是减少心脏病的风险和并发症。”

在此次研究中,史蒂夫使用的古饮食有些特别,比如他可能早餐吃一盘鸡蛋、蔬菜和咸肉;午餐吃罗非鱼和菠菜;晚餐吃的是低碳烧烤酱和混合蔬菜。饭间,他对吃低碳水化合物的小吃,像煮熟的鸡蛋,奶酪,金枪鱼罐头,鲑鱼,沙丁油鱼,和一些蔬菜,如芹菜、青椒、花椰菜、菜花。他通常一天只吃一顿或两顿饭。

古饮食适合你吗?

研究人员表示,像史蒂夫这样的故事当然不是闻所未闻,因为患有2型糖尿病的人的身体仍然会自行产生胰岛素,而且这足以处理古饮食中少量的碳水化合物。但这可能不是一个永久的解决办法。“不管是古饮食还是限制碳水化合物量的饮食都是如此。”

患有1型糖尿病的人,如果根本不产生胰岛素,就无法通过遵循传统饮食停止服用糖尿病药物,但这种方法可能有助于调节他们的血糖水平。一项小的研究发现,那些在低碳水化合物饮食中坚持了四年的1型患者并不像在节食前那样需要更多的胰岛素,而且他们的血糖水平也更均衡。

有兴趣尝试古饮食的糖尿病患者,应该在开始计划之前,咨询医生或注册营养师。如果有肾脏问题或正在服用某些药物,可能无法安全地遵循计划。因为古饮食也涉及大量的“块状”食物,那些有肠道疾病的人也可能无法忍受。如果肠道运动有问题,也会有很多问题。

不确定是否遵循传统饮食来控制糖尿病的人,可以在目前的饮食中加入一些它的原理,比如多吃新鲜食品,加工食品。

史蒂夫在接受采访时表示:“我认为人们一般吃太多的碳水化合物了,可以把多余的东西处理掉。古生活方式是一种生活方式,我由于2型糖尿病与这种生活方式相遇,我会一直坚持下去的。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1474418, encodeId=569314e441897, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584110, encodeId=1fed158411085, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284183, encodeId=241b28418350, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 01 14:41:15 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284161, encodeId=47332841611c, content=有用吗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/01/b119cf52e9aa56332062f9070d8f4c26.jpg, createdBy=bc4d2263557, createdName=风飞, createdTime=Thu Feb 01 12:47:23 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284159, encodeId=31432841595c, content=有待考证, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Feb 01 12:34:09 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284155, encodeId=edc12841559a, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Thu Feb 01 12:19:29 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1474418, encodeId=569314e441897, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584110, encodeId=1fed158411085, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284183, encodeId=241b28418350, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 01 14:41:15 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284161, encodeId=47332841611c, content=有用吗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/01/b119cf52e9aa56332062f9070d8f4c26.jpg, createdBy=bc4d2263557, createdName=风飞, createdTime=Thu Feb 01 12:47:23 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284159, encodeId=31432841595c, content=有待考证, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Feb 01 12:34:09 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284155, encodeId=edc12841559a, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Thu Feb 01 12:19:29 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1474418, encodeId=569314e441897, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584110, encodeId=1fed158411085, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284183, encodeId=241b28418350, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 01 14:41:15 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284161, encodeId=47332841611c, content=有用吗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/01/b119cf52e9aa56332062f9070d8f4c26.jpg, createdBy=bc4d2263557, createdName=风飞, createdTime=Thu Feb 01 12:47:23 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284159, encodeId=31432841595c, content=有待考证, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Feb 01 12:34:09 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284155, encodeId=edc12841559a, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Thu Feb 01 12:19:29 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
    2018-02-01 changjiu

    学习一下谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1474418, encodeId=569314e441897, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584110, encodeId=1fed158411085, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284183, encodeId=241b28418350, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 01 14:41:15 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284161, encodeId=47332841611c, content=有用吗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/01/b119cf52e9aa56332062f9070d8f4c26.jpg, createdBy=bc4d2263557, createdName=风飞, createdTime=Thu Feb 01 12:47:23 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284159, encodeId=31432841595c, content=有待考证, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Feb 01 12:34:09 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284155, encodeId=edc12841559a, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Thu Feb 01 12:19:29 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
    2018-02-01 风飞

    有用吗!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1474418, encodeId=569314e441897, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584110, encodeId=1fed158411085, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284183, encodeId=241b28418350, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 01 14:41:15 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284161, encodeId=47332841611c, content=有用吗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/01/b119cf52e9aa56332062f9070d8f4c26.jpg, createdBy=bc4d2263557, createdName=风飞, createdTime=Thu Feb 01 12:47:23 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284159, encodeId=31432841595c, content=有待考证, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Feb 01 12:34:09 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284155, encodeId=edc12841559a, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Thu Feb 01 12:19:29 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
    2018-02-01 smartxiuxiu

    有待考证

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1474418, encodeId=569314e441897, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584110, encodeId=1fed158411085, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Sat Feb 03 03:13:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284183, encodeId=241b28418350, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 01 14:41:15 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284161, encodeId=47332841611c, content=有用吗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/01/b119cf52e9aa56332062f9070d8f4c26.jpg, createdBy=bc4d2263557, createdName=风飞, createdTime=Thu Feb 01 12:47:23 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284159, encodeId=31432841595c, content=有待考证, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Feb 01 12:34:09 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284155, encodeId=edc12841559a, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Thu Feb 01 12:19:29 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
    2018-02-01 杨利洪

    学习了提高了

    0

相关资讯

警惕!2型糖尿病恶化和失控的“十大”皮肤标志

糖尿病是增长最快的长期慢性疾病,影响全球数百万人.。在美国,超过二千五百万人患有糖尿病。其中约75%人患有2型糖尿病,与肥胖或超重有关。研究人员认为,糖尿病的流行将继续升级,并预测在2050年,三分之一的美国人将患有糖尿病。

Invest Ophthalmol Vis Sci:多巴胺缺乏症介导了糖尿病小鼠早期视杆驱动的内部视网膜功能障碍

美国佐治亚州亚特兰大Emory大学眼科学系的Kim MK近日在Invest Ophthalmol Vis Sci发表,他们发现,早期糖尿病的内部视网膜功能障碍是由rod信号途径功能紊乱和多巴胺(DA)缺陷介导的。振荡电位(OPs)延迟可用于鉴定糖尿病视网膜病变中最早的功能缺陷。

Diabetes Care:血浆结缔组织生长因子(CTGF/CCN2)水平预测糖尿病患者心肌梗死!

由此可见,该研究表明高水平的CTGF/CCN2可预测2型糖尿病患者未来的MI和心血管死亡风险。

Lancet Diabetes Endo:索马鲁肽对血糖控制和体重减轻的效果优于度拉糖肽

研究认为,高低2个剂量组索马鲁肽对血糖控制和体重减轻的效果均优于度拉糖肽

J Clin Invest:美科学家在血管研究中发现“逆转糖尿病”的有效新方法!

关于胰岛素如何通过血液代谢细胞中葡萄糖的新见解可能会带来胰岛素抵抗的新治疗,这种情况通常先于2型糖尿病。

Jama Intern Med:哺乳时间长可减低患糖尿病的风险

近期,JAMA Intern Med杂志上发表一篇文章,提示哺乳持续时间与2型糖尿病的发病率相关。研究人员在美国多个中心进行一以社区为基础的为期30年的前瞻性队列研究,共招募了1238位18-30岁的招募时(1985-1986年)无糖尿病的至少分娩过一次的年轻女性(白种人和黑种人),在随后的30年里(1986-2016年),进行7次糖尿病筛查。总的哺乳持续时间划分为无、0-6个月、6-12个月和1